We observed the HER3 mutation T355I to be oncogenic in the absence of HER2 over-expression in ER+ breast cancer, a novel finding and clinically relevant as this mutation has been identified in 4 ER+ breast cancer patients. Here, ERBB2 is linked to breast cancer.